In healthy children there is a 25% excess of IGFBPs over IGF, while, in pre-terminal renal failure, IGFBPs are 150% in excess of IGFs, and in end-stage renal disease they are 200% in excess, thus reducing the bioavailability of IGF [21]. This evidence concerns the gene IGF1 and stage 5 chronic kidney disease.